ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Integrated Multi-Channel Automatic Cellular Profiling (iMAP) System for Cholangiocarcinoma Diagnosis.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cholangiocarcinoma (CCA) is a highly lethal malignant tumor with a five-year survival rate below 10%. Clinical challenges include the absence of effective screening tools, the gradual progression until symptoms manifest, and the low diagnostic accuracy of CCA tissue due to the paucicellular nature of specimens obtained during an intervention. To address these challenges, an integrated multi-channel automatic cellular profiling (iMAP) system is developed for robust analysis of endoscopically obtained biliary specimens. Brushing cytology samples are introduced into a microfluidic chip to enrich and capture suspicious epithelial cells while eliminating blood and fibrotic cells. The captured cells are subsequently immunostained with fluorescent antibodies for further molecular analysis. The entire process, from sample loading to diagnosis, is fully automated and completed within 30 min. After validating the system with in vitro cell lines, iMAP is applied to analyze clinical brush specimens. In a pilot clinical study with 56 patient samples, good clinical diagnostic accuracy (AUC = 0.85) is demonstrated for CCA using a four-marker combination (MUC1, EpCAM, EGFR, and MARS1). The fully automated iMAP can serve as a complementary technology to the existing clinical cytopathology workflow, thereby minimizing sample loss and enhancing diagnostic accuracy through multiplexing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.